Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 5 | 2024 | 49 | 3.500 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2023 | 16 | 1.890 |
Why?
|
| Echocardiography | 2 | 2024 | 155 | 1.100 |
Why?
|
| Stroke Volume | 3 | 2024 | 341 | 1.000 |
Why?
|
| Bayes Theorem | 1 | 2023 | 79 | 0.890 |
Why?
|
| Research Design | 1 | 2022 | 308 | 0.740 |
Why?
|
| Migraine Disorders | 3 | 2024 | 67 | 0.610 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 760 | 0.560 |
Why?
|
| Prospective Studies | 6 | 2024 | 2271 | 0.560 |
Why?
|
| Neoplasms | 1 | 2022 | 691 | 0.530 |
Why?
|
| Humans | 24 | 2024 | 31775 | 0.490 |
Why?
|
| Acute Disease | 3 | 2023 | 252 | 0.450 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 20 | 0.440 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 471 | 0.350 |
Why?
|
| Quality of Life | 2 | 2023 | 918 | 0.270 |
Why?
|
| Adult | 8 | 2024 | 9313 | 0.230 |
Why?
|
| Retinal Diseases | 1 | 2024 | 20 | 0.230 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2023 | 32 | 0.230 |
Why?
|
| Cardiovascular System | 1 | 2023 | 42 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2024 | 122 | 0.220 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 44 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 48 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 61 | 0.220 |
Why?
|
| Prognosis | 2 | 2024 | 1493 | 0.210 |
Why?
|
| Tachycardia, Sinus | 1 | 2022 | 3 | 0.210 |
Why?
|
| Drug Combinations | 1 | 2022 | 93 | 0.210 |
Why?
|
| Electrolytes | 1 | 2022 | 11 | 0.210 |
Why?
|
| Oxidative Stress | 1 | 2024 | 229 | 0.210 |
Why?
|
| Epilepsy | 1 | 2023 | 82 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 143 | 0.210 |
Why?
|
| Ventricular Function, Right | 1 | 2022 | 17 | 0.210 |
Why?
|
| Telemedicine | 1 | 2024 | 98 | 0.210 |
Why?
|
| Allostasis | 1 | 2022 | 12 | 0.210 |
Why?
|
| Critical Illness | 1 | 2023 | 87 | 0.210 |
Why?
|
| Nurses | 1 | 2021 | 15 | 0.200 |
Why?
|
| Food Labeling | 1 | 2021 | 1 | 0.200 |
Why?
|
| Functional Food | 1 | 2021 | 1 | 0.200 |
Why?
|
| Food Packaging | 1 | 2021 | 2 | 0.200 |
Why?
|
| Computer Simulation | 1 | 2022 | 219 | 0.200 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 9 | 0.200 |
Why?
|
| Microcirculation | 1 | 2021 | 65 | 0.190 |
Why?
|
| Premenopause | 1 | 2021 | 42 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2024 | 1428 | 0.190 |
Why?
|
| Ovary | 1 | 2021 | 58 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2021 | 70 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2022 | 629 | 0.190 |
Why?
|
| Middle Aged | 6 | 2024 | 11795 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 409 | 0.180 |
Why?
|
| Female | 8 | 2024 | 19817 | 0.180 |
Why?
|
| Aged | 4 | 2024 | 10263 | 0.160 |
Why?
|
| Risk Factors | 2 | 2024 | 3835 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2022 | 631 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 1 | 0.150 |
Why?
|
| Interleukin-15 | 1 | 2017 | 4 | 0.150 |
Why?
|
| Interleukin-7 | 1 | 2017 | 11 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2017 | 30 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 11 | 0.140 |
Why?
|
| Hypertension | 1 | 2024 | 956 | 0.140 |
Why?
|
| Male | 5 | 2024 | 19052 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2015 | 37 | 0.130 |
Why?
|
| Apoptosis | 1 | 2017 | 354 | 0.120 |
Why?
|
| Social Support | 1 | 2015 | 179 | 0.120 |
Why?
|
| Qualitative Research | 2 | 2023 | 166 | 0.100 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 240 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2023 | 534 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 894 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1522 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2024 | 5 | 0.060 |
Why?
|
| Arginine | 1 | 2024 | 17 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 38 | 0.060 |
Why?
|
| Aromatase | 1 | 2023 | 9 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2024 | 82 | 0.060 |
Why?
|
| United States | 2 | 2024 | 3920 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 192 | 0.060 |
Why?
|
| Birth Weight | 1 | 2023 | 47 | 0.060 |
Why?
|
| Fear | 1 | 2023 | 48 | 0.060 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 2023 | 1 | 0.060 |
Why?
|
| Seizures | 1 | 2023 | 64 | 0.060 |
Why?
|
| Universities | 1 | 2024 | 144 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2024 | 169 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 167 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 304 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 98 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 178 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 206 | 0.050 |
Why?
|
| Food Handling | 1 | 2021 | 6 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 88 | 0.050 |
Why?
|
| Adenosine | 1 | 2021 | 59 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2023 | 665 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2022 | 134 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 103 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2023 | 218 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2022 | 159 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 158 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 285 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2022 | 191 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 136 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 225 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 754 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 188 | 0.040 |
Why?
|
| Kidney | 1 | 2023 | 514 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 663 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 913 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1186 | 0.040 |
Why?
|
| Depression | 1 | 2021 | 441 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 12 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 56 | 0.040 |
Why?
|
| Adolescent | 1 | 2023 | 3509 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 144 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 1323 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 598 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 493 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 607 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2473 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7446 | 0.020 |
Why?
|